Sanofi has entered a definitive agreement to acquire Bioverativ, Inc., a biopharma company focused on therapies for hemophilia and other rare blood disorders, for approximately $11.6 billion. Bioverativ was created from Biogen’s hemophilia-focused spinoff launched in early 2017.     Hemophilia represents the largest market for rare diseases, with approximately 181,000 people affected worldwide, which is expected to grow above 7% per year through 2022. Bioverativ has approximately $10 billion i...